PT1023903E - Utilizacao de bacterias vivas atenuadas para o fabrico de uma vacina submucosa - Google Patents

Utilizacao de bacterias vivas atenuadas para o fabrico de uma vacina submucosa

Info

Publication number
PT1023903E
PT1023903E PT00200216T PT00200216T PT1023903E PT 1023903 E PT1023903 E PT 1023903E PT 00200216 T PT00200216 T PT 00200216T PT 00200216 T PT00200216 T PT 00200216T PT 1023903 E PT1023903 E PT 1023903E
Authority
PT
Portugal
Prior art keywords
vaccine
manufacture
submucose
atenuated
live bacteria
Prior art date
Application number
PT00200216T
Other languages
English (en)
Inventor
Antonius Arnoldus Chris Jacobs
Danny Goovaerts
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of PT1023903E publication Critical patent/PT1023903E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/82—Viral vaccine for equine species, e.g. horses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT00200216T 1999-01-26 2000-01-20 Utilizacao de bacterias vivas atenuadas para o fabrico de uma vacina submucosa PT1023903E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99200202 1999-01-26

Publications (1)

Publication Number Publication Date
PT1023903E true PT1023903E (pt) 2004-04-30

Family

ID=8239828

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00200216T PT1023903E (pt) 1999-01-26 2000-01-20 Utilizacao de bacterias vivas atenuadas para o fabrico de uma vacina submucosa

Country Status (10)

Country Link
US (2) US20040120970A1 (pt)
EP (1) EP1023903B1 (pt)
JP (1) JP4339978B2 (pt)
AT (1) ATE257713T1 (pt)
AU (1) AU761515B2 (pt)
CA (1) CA2296965A1 (pt)
DE (1) DE60007668T2 (pt)
DK (1) DK1023903T3 (pt)
ES (1) ES2214217T3 (pt)
PT (1) PT1023903E (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
WO2009004995A1 (ja) * 2007-06-29 2009-01-08 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. 生理活性物質を定着および発現させる方法
GB0801326D0 (en) * 2008-01-24 2008-03-05 Animal Health Trust Vaccines
KR101210082B1 (ko) * 2010-10-15 2012-12-07 주식회사 동방 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법
KR101694676B1 (ko) * 2015-12-10 2017-01-10 우진 비앤지 주식회사 말 선역 질병원인 국내 분리 스트렙토코커스 이콰이 균주 및 이를 포함하는 백신
CA3108051A1 (en) 2018-08-10 2020-02-13 Meiji Seika Pharma Co., Ltd. Bacteriophage preparation
CN112973157A (zh) * 2021-02-04 2021-06-18 广西田东锦盛化工有限公司 一种用于氯碱生产的盐水浓缩装置
CN113244664A (zh) * 2021-05-12 2021-08-13 伍俊雄 一种用于疫苗破乳及分离的装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2033223B (en) * 1978-09-01 1983-09-14 Secr Social Service Brit Antigen fromstreptococcus mutans for protection against dental caries
JPS6037734B2 (ja) 1978-10-12 1985-08-28 住友電気工業株式会社 管状臓器補綴材及びその製造方法
WO1982004396A1 (en) * 1981-06-19 1982-12-23 Russell Roy Robert Baird Protection against dental caries
IE940698L (en) * 1984-04-05 1985-10-05 Univ Missouri Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
AR241545A1 (es) * 1985-07-12 1992-08-31 Cornell Res Foundation Inc Un metodo para preparar una cepa de s. equi avirulenta a.t.c.c. 53186 para equinos.
BE1008103A3 (fr) 1994-04-22 1996-01-16 Pantochim Sa Procede de preparation de catalyseurs au vanadium et phosphore et leur utilisation pour la production d'anhydride maleique.
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
US5895756A (en) * 1997-04-11 1999-04-20 The Board Of Trustees Of The University Of Texas System Non-antibiotic system for selection of recombinant mycobacteria
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
US6682745B1 (en) * 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
US6344201B1 (en) * 1998-03-31 2002-02-05 Anthony T. Maurelli Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cadA, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections

Also Published As

Publication number Publication date
AU761515B2 (en) 2003-06-05
DE60007668D1 (de) 2004-02-19
JP4339978B2 (ja) 2009-10-07
US20110123571A1 (en) 2011-05-26
US20040120970A1 (en) 2004-06-24
US8084040B2 (en) 2011-12-27
EP1023903A1 (en) 2000-08-02
DK1023903T3 (da) 2004-05-10
ATE257713T1 (de) 2004-01-15
AU1355700A (en) 2000-07-27
ES2214217T3 (es) 2004-09-16
EP1023903B1 (en) 2004-01-14
JP2000309542A (ja) 2000-11-07
DE60007668T2 (de) 2004-12-02
CA2296965A1 (en) 2000-07-26

Similar Documents

Publication Publication Date Title
ATE556596T1 (de) Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion
CY1113766T1 (el) Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
GT200000190A (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas-4-carboxiamino-2-sustituidas.
ATE140687T1 (de) Bakterientötende zweiwertiges silber enthaltende zusammensetzungen
CU23006A3 (es) Nuevos ésteres derivados de compuestos fenil-ciclonuevos ésteres derivados de compuestos fenil-ciclohexil sustituidos hexil sustituidos
HN1999000125A (es) Nuevos derivados sustituidos del pirazol
DE69526854D1 (de) Physikalisch modifizierte abbaubare thermoplastische zusammensetzung
EA200870564A1 (ru) Новые производные бензотиазинона и их применение в качестве антибактериальных средств
PT1023903E (pt) Utilizacao de bacterias vivas atenuadas para o fabrico de uma vacina submucosa
UY26256A1 (es) Amidas de ácidos carboxílicos, medicamentos que contienen estos compuestos, su utilización y su preparación
ES2077199T3 (es) Nuevas piperacinas 1,4-disustituidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
UY26929A1 (es) Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
DE60035639D1 (de) Hydroxydiphenyletherverbindungen
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
AR030735A1 (es) Un procedimiento para la produccion de un extracto de champinon natural
NO20014240L (no) C16-umettede FP-selektive prostaglandinanaloger
UY26265A1 (es) Compuestos calciolíticos
EA199900534A1 (ru) Имидазопиридазины
ES2163220T3 (es) Dioxacicloalcan-8-ona.
DK0548103T3 (da) Anvendelse af pyridylmethylsulfinyl-1H-benzimidazolderivater til behandling af sygdomme, der er fremkaldt af Helicobacter-bakterier
PT894500E (pt) Vacina para streptococcus equi
DOP2001000140A (es) Aril y heteroarilsulfonatos
SE9200502D0 (sv) Novel antioxidants
ES2171838T3 (es) Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para el tratamiento del trastorno bipolar.